Published • loading... • Updated
Contineum, J&J’s depression drug fails to meet mid-stage trial goal
Contineum said the drug was well-tolerated and showed no new safety signals, but shares fell nearly 8% after the study missed its endpoint.
Summary by WTVB
3 Articles
3 Articles
Contineum, J&J’s depression drug fails to meet mid-stage trial goal - Regional Media News
Sept 15 (Reuters) - Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study. Here are the details: • The trial was testing the drug, JNJ-5120 or PIPE-307, in patients [...]
Contineum, J&J’s depression drug fails to meet mid-stage trial goal
Sept 15 (Reuters) - Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study. Here are the details: • The trial was testing the drug, JNJ-5120 or PIPE-...
Coverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
